<DOC>
	<DOCNO>NCT00154661</DOCNO>
	<brief_summary>hypothesize PTX might effective lower proteinuria modulate renal MCP-1 production human glomerulonephritis .</brief_summary>
	<brief_title>Evaluation Clinical Efficacy Pentoxifylline Patients With Glomerulonephritis</brief_title>
	<detailed_description>Pentoxifylline ( PTX ) phosphodiesterase inhibitor widely use treatment peripheral vascular occlusive disorder . In addition , PTX show ability attenuate nephrotic syndrome secondary membranous glomerulonephritis lupus nephritis , reduce subnephrotic proteinuria due early advanced diabetic nephropathy . However , data respect effect non-nephrotic primary glomerular disease lack . Moreover , anti-proteinuric effect PTX largely attribute down-regulation TNF-a , remain unknown whether mediator , especially MCP-1 , also affect PTX . Because previous work show PTX attenuate proteinuria suppresses renal MCP-1 mRNA expression experimental glomerulonephritis rat , hypothesize PTX might effective lower proteinuria modulate renal MCP-1 production human glomerulonephritis . This study thereby conduct investigate potential anti-proteinuric anti-MCP-1 effect PTX subnephrotic patient primary glomerular disease .</detailed_description>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>glomerular disease subnephrotic proteinuria DM , hepatitis , systemic immunologic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>glomerulonephritis</keyword>
</DOC>